Curated News
By: NewsRamp Editorial Staff
February 13, 2026
Helus Pharma Reports Q3 2025 Results, Advances Mental Health Therapies
TLDR
- Helus Pharma's strong cash position of $195.1 million and upcoming 2026 clinical data milestones provide investors with potential advantages in the mental health treatment market.
- Helus Pharma reported a $42.7 million net loss as operating expenses increased to advance its Phase 3 HLP003 program for depression and Phase 2 HLP004 program for anxiety.
- Helus Pharma's novel serotonergic agonists aim to provide durable improvements in mental health, addressing unmet needs for people suffering from depression and anxiety disorders.
- Helus Pharma completed a leadership transition and corporate rebranding while developing synthetic molecules designed to activate serotonin pathways that promote neuroplasticity.
Impact - Why it Matters
This news matters because Helus Pharma's progress in developing novel serotonergic agonists could revolutionize mental health treatment, addressing the large unmet needs for conditions like depression and anxiety. With HLP003's Breakthrough Therapy Designation and upcoming clinical data in 2026, the company is poised to potentially introduce more effective, durable therapies that improve patient outcomes. For investors, the strong cash position and strategic rebranding signal financial stability and growth potential in the competitive biotech sector, while for patients and healthcare providers, it offers hope for new treatment options in a field often limited by existing medications.
Summary
Helus Pharma, formerly known as Cybin Inc., has announced its unaudited financial results for the third quarter ending December 31, 2025, showcasing a robust cash position of $195.1 million alongside a net loss of $42.7 million. The clinical-stage pharmaceutical company, which trades on NASDAQ and Cboe CA under the ticker HELP, is making significant strides with its proprietary novel serotonergic agonists (NSAs), specifically HLP003 and HLP004. These synthetic molecules are designed to activate serotonin pathways to promote neuroplasticity, targeting major depressive disorder and generalized anxiety disorder, respectively. The company's leadership transition and corporate rebranding mark a strategic shift as it advances its clinical programs, with upcoming data milestones anticipated in 2026.
Helus Pharma's HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential in the adjunctive treatment of major depressive disorder, while HLP004 is progressing through Phase 2 trials for generalized anxiety disorder. The company emphasizes its expanding intellectual property portfolio and strengthened balance sheet, which supports ongoing clinical activities despite increased operating expenses. For more details, investors can view the full press release at https://ibn.fm/VigPf, and to stay updated, the latest news is available in the company's newsroom at https://ibn.fm/HELP. Helus Pharma operates globally, with a presence in Canada, the United States, the United Kingdom, and Ireland, and encourages stakeholders to visit www.helus.com for further information.
This news release was disseminated by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, focusing on biotechnology and life sciences sectors. BioMedWire provides enhanced press release distribution and social media outreach to ensure maximum impact for companies like Helus Pharma. The platform's services include access to a vast network of wire solutions and editorial syndication to over 5,000 outlets, helping to cut through information overload in today's market. For more on BioMedWire's offerings, visit https://www.BioMedWire.com, and note that this content may include paid advertising, as indicated in the disclaimer.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Reports Q3 2025 Results, Advances Mental Health Therapies
